BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33581342)

  • 1. The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.
    Ye L; Creaney J; Redwood A; Robinson B
    J Thorac Oncol; 2021 Jun; 16(6):922-932. PubMed ID: 33581342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.
    Sneddon S; Rive CM; Ma S; Dick IM; Allcock RJN; Brown SD; Holt RA; Watson M; Leary S; Lee YCG; Robinson BWS; Creaney J
    Oncoimmunology; 2020; 9(1):1684713. PubMed ID: 32002298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
    Su S; Chen F; Xu M; Liu B; Wang L
    Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy targeting neoantigens.
    Lu YC; Robbins PF
    Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer Vaccine Focused on Neoantigens].
    Shindo Y; Hazama S; Nagano H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
    Zhao W; Wu J; Chen S; Zhou Z
    Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
    Ding Z; Li Q; Zhang R; Xie L; Shu Y; Gao S; Wang P; Su X; Qin Y; Wang Y; Fang J; Zhu Z; Xia X; Wei G; Wang H; Qian H; Guo X; Gao Z; Wang Y; Wei Y; Xu Q; Xu H; Yang L
    Signal Transduct Target Ther; 2021 Jan; 6(1):26. PubMed ID: 33473101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse Neoantigens and the Development of Cancer Therapies.
    Srivastava RM; Purohit TA; Chan TA
    Semin Radiat Oncol; 2020 Apr; 30(2):113-128. PubMed ID: 32381291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigens and NK Cells: "Trick or Treat" the Cancers?
    Lv D; Khawar MB; Liang Z; Gao Y; Sun H
    Front Immunol; 2022; 13():931862. PubMed ID: 35874694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigens: promising targets for cancer therapy.
    Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
    Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.